Evidence map›Paper›PMID 40832278›Full record

ArticlebioRxiv : the preprint server for biology2025

A recombinant expression system for the

Pavla Fajtova, Hanxiao Zhang, Liam Urich, Elany Barbosa da Silva, Cesar Hoffmann da Silva, Jehad Almaliti, Momen Al-Hindy, Evzen Boura, Laura A Kirkman, Gang Lin and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Pavla FajtovaCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-4029-0706
Hanxiao ZhangCancer Metabolism and Microenvironment Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 92037, USA.ORCID 0000-0001-6416-1696
Liam UrichCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0009-0006-3104-0939
Elany Barbosa da SilvaCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Cesar Hoffmann da SilvaCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Jehad AlmalitiDepartment Pharmaceutical Sciences, College of Pharmacy, The University of Jordan, Amman, Jordan.
Momen Al-HindyCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, USA.
Evzen BouraInstitute of Organic Chemistry and Biochemistry AS CR, v.v.i., Prague, Czech Republic.ORCID 0000-0002-9652-4065
Laura A KirkmanDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10065, United States.ORCID 0000-0003-4085-5540
Gang LinDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10065, United States.
Matthew BogyoDepartment of Pathology, Stanford University School of Medicine, Stanford, California 94305, United States.ORCID 0000-0003-3753-4412
David A FidockDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, United States.
William H GerwickCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Jianhua ZhaoCancer Metabolism and Microenvironment Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 92037, USA.ORCID 0000-0002-4997-766X
Anthony J O'DonoghueCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Proteasome inhibitors against mucosal protozoan pathogensR01AI158612 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, O'DONOGHUE, ANTHONY JOHN · 2021 to 2025
$3.2M
Molecular mechanisms underlying the assembly of the human proteasome and endogenous protein complexesR35GM147487 · NIGMS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Jianhua Zhao · 2022 to 2026
$2.4M
The catalytic core of the proteasome as a drug target to treat Human African TrypanosomiasisR21AI171824 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAFFREY, CONOR, O'DONOGHUE, ANTHONY JOHN · 2022 to 2023
$435k
Selective proteasome inhibitors for trichomoniasisR21AI146387 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, O'DONOGHUE, ANTHONY JOHN · 2019 to 2020
$433k
Exploring the proteasome as a new drug target to treat schistosomiasisR21AI133393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI O'DONOGHUE, ANTHONY JOHN · 2017 to 2018
$426k
Acquisition of a CMOS Imaging Device for the T12 at SBPS10OD026926 · OD · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ZHAO, JIANHUA · 2019 to 2019
$207k
NCI NIH HHS P30 CA030199NIAID NIH HHS R01 AI158612NIAID NIH HHS R21 AI133393NIAID NIH HHS R21 AI146387NIAID NIH HHS R21 AI171824NIGMS NIH HHS R35 GM147487NIH HHS S10 OD026926
6 · The paper itself

Abstract

The

Identifiers

PMID40832278
PMCPMC12363949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.